1	
2	
3	
4	Full title (164/200 characters): Costs of home-delivered
5	antiretroviral therapy refills for persons living with HIV: evidence
6	from a pilot randomized controlled trial in KwaZulu-Natal, South
7	Africa
8	
9	Short title (70/70 characters): Costs of home-delivered antiretroviral
10	therapy refills in South Africa
11	
12	
13	Ashley S. Tseng <sup>1,2*</sup> , Ruanne V. Barnabas <sup>3,4</sup> , Alastair van Heerden <sup>5,6</sup> , Xolani Ntinga <sup>5</sup> , Maitreyi
14	Sahu <sup>7</sup>
15 16	
17	<sup>1</sup> Department of Epidemiology, University of Washington, Seattle, Washington, United States of
18	America
19	<sup>2</sup> Department of Global Health, University of Washington, Seattle, Washington, United States of
20 21	America <sup>3</sup> Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital,
22	Harvard Medical School, Boston, Massachusetts, United States of America
23	<sup>4</sup> Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston,
24	Massachusetts, United States of America
25	<sup>5</sup> Center for Community Based Research, Human Sciences Research Council, Sweetwaters,
26 27	KwaZulu-Natal, South Africa <sup>6</sup> South African Medical Research Council/Wits Developmental Pathways for Health Research
28	Unit, Department of Paediatrics, School of Clinical Medicine, Faculty of Health Sciences,
29	University of the Witwatersrand, Johannesburg, Gauteng, South Africa
30	<sup>7</sup> Department of Health Metrics Sciences, University of Washington, Seattle, Washington, United
31	States of America
32 33	* Corresponding author
34	E-mail: ashleystseng@gmail.com (AST)
35	
36	Keywords: HIV/AIDS; sub-Saharan Africa; HIV treatment; ART, costing
37 38	Word count: 4,119 words
39	
55	

### 40 Abstract (299/300 words)

Antiretroviral therapy (ART) is needed across the lifetime to maintain viral suppression for 41 42 people living with HIV. In South Africa, obstacles to reliable access to ART persist and are magnified in rural areas, where HIV services are also typically costlier to deliver. A recent pilot 43 44 randomized study (the Deliver Health Study) found that home-delivered ART refills, provided at 45 a low user fee, effectively overcame logistical barriers to access and improved clinical outcomes in rural South Africa. In the present costing study using the payer perspective, we conducted 46 47 retrospective activity-based micro-costing of home-delivered ART within the Deliver Health 48 Study and when provided at-scale (in a rural setting), and compared to facility-based costs using 49 provincial expenditure data (covering both rural and urban settings). Within the context of the pilot 50 Deliver Health Study which had an average of three deliveries per day for three days a week, home-delivered ART cost (in 2022 USD) \$794 in the first year and \$714 for subsequent years per 51 client after subtracting client fees, compared with \$167 per client in provincial clinic-based care. 52 53 We estimated that home-delivered ART can reasonably be scaled up to 12 home deliveries per day 54 for five days per week in the rural setting. When delivered at scale, home-delivered ART cost \$267 55 in the first year and \$183 for subsequent years per client. Average costs of home delivery further decreased when increasing the duration of refills from three-months to six- and 12-month scripts 56 (from \$183 to \$177 and \$135 per client, respectively). Personnel costs were the largest cost for 57 58 home-delivered refills while ART drug costs were the largest cost of clinic-based refills. When provided at scale, home-delivered ART in a rural setting not only offers clinical benefits for a hard-59 60 to-reach population but is also comparable in cost to the provincial standard of care.

## 61 Introduction

62 Until a cure for HIV is available, reliable access to antiretroviral therapy (ART) is needed across the lifetime to maintain viral suppression. South Africa has one of the highest burdens of 63 64 HIV worldwide with an HIV prevalence of 16% among adults aged 15 and older and a total of 7.8 65 million people with HIV who require lifetime ART [1]. In the past two decades, the South African government has invested heavily in their HIV programme, and has made great progress towards 66 achieving the UNAIDS 95-95-95 treatment targets: as of 2022, 90% of South African adults with 67 HIV knew their status, 91% of adults who knew their status were on ART, and 94% of people on 68 69 ART were virally suppressed [1]. However, the status of HIV control varies considerably across 70 the nation, with KwaZulu-Natal province continuing to have the highest HIV prevalence in the country (22%) [1] and rural farming communities reporting higher HIV prevalence than urban 71 areas (18% vs. 13%) [2]. Access to HIV care is further constrained by slowing government funding 72 73 which has not matched the level of demand [3], particularly in rural areas where the cost of 74 successfully treating HIV is higher due to logistical barriers, supply chain considerations, and 75 staffing challenges [4]. In light of these rural/urban disparities in HIV outcomes and costs, novel 76 and low-cost strategies to address gaps in HIV care in rural South Africa are critically needed.

A number of strategies have been proposed to improve HIV outcomes and reduce the burden of care associated with one to three-month ART refill visits for both clients and health systems [5]. In particular, the World Health Organization now recommends Differentiated Service Delivery (DSD) for HIV care, which involves tailoring programs to accommodate client needs to improve HIV treatment outcomes and reduce health system burden [6]. Various client-centered DSD mechanisms are being proposed to increase viral suppression by overcoming barriers to accessing HIV care including long wait times at clinics, transportation barriers, and social stigma

[7–9]. As a result, alternative ART dispensing mechanisms which reduce clinic burden including
home delivery of medications are being explored and have had demonstrated feasibility and
success in improving client adherence in South Africa [5,10–12].

87 The recent Deliver Health Study found that home-delivered ART and monitoring for a 88 small user fee increased viral suppression by 21% compared to standard facility-based care among 89 162 participants in rural KwaZulu-Natal [13]; however, the costs of this program have not 90 previously been quantified. The objective of the present study was to estimate the cost of homedelivered ART for adults living with HIV in rural South Africa (1) within the context of the pilot 91 92 study and (2) when provided at-scale, compared to standard clinic-based ART resupply. A 93 secondary objective was to identify cost drivers for each mode of ART delivery. In a sensitivity analysis, we also estimated cost savings when home-delivered ART used multi-month refill 94 95 scripts. This study aims to inform the South African National Department of Health's (NDoH) strategy to improve HIV treatment outcomes and reduce health system burden in rural South 96 97 Africa.

### 98 Materials and Methods

### 99 Deliver Health Study

100 The Deliver Health Study (NIH R21MH115770; ClinicalTrials.gov Identifier: 101 NCT04027153) was a pilot randomized trial of home ART delivery, monitoring, and ART 102 resupply conducted in three rural and peri-urban communities in uMgungundlovu District, 103 KwaZulu-Natal from October 2019 to December 2020. The detailed study procedures have been 104 previously published [14], and are also summarized in the S1 File flow map. Briefly, 162 ART-105 eligible [15] adults aged 18 or over with HIV were identified through home and mobile van HIV 106 testing and counselling and at HIV clinics. Following the enrollment and ART initiation visit,

clients were randomized to receive either home delivery of HIV care which was provided for a 107 108 small user fee of 30–90 South African Rand (ZAR) (2–7 United States Dollars [USD]), or standard 109 clinic-based ART follow-up care at a health center of choice within the study catchment area. 110 Home delivery of HIV care was provided leveraging an optimized delivery algorithm to reduce 111 travel times and associated costs, described further in the S2 File. For the home delivery arm of 112 the pilot study, study staff made deliveries three days per week, spent an average of 26 minutes per home delivery of ART (including transportation time), and made an average of three deliveries 113 a day. Home delivery was at first implemented by a team of three (nurse, driver, data collector), 114 115 but staffing was later reduced to just the nurse due to pandemic social distancing restrictions (S1 116 File). All Deliver Health Study participants received the TDF/FTC/EFV ART regimen for the 117 treatment of HIV.

#### **118 Ethics statement and declarations**

Ethical approval was obtained from the Human Sciences Research Council Research Ethics
Committee in South Africa (REC 1/21/11/18) and the University of Washington Institutional
Review Board in Seattle, Washington, United States (STUDY00005739). All study participants
provided written informed consent per local ethics committee requirements.

Access to Deliver Health Study data was originally granted on March 8, 2022 to AST. AST
 had access to information that could potentially identify participants after data collection,
 specifically participant locator information.

**126** Study population

#### 127 Deliver Health Study participant demographics

A total of 155 adults living with HIV completed follow-up in the Deliver Health Study, 81
(52%) of whom received home-delivered ART refills and monitoring and 74 (48%) of whom

received clinic-based care. The median age of participants was 38 years (interquartile range: 12),
and 72 (47%) were women. Seventy-one (88%) people living with HIV in the home-delivery group
were virally suppressed at study exit compared to 55 (74%) people living with HIV in the clinicbased care group. The average monthly salary of participants randomized to the home delivery
group, self-reported at baseline, was 1376 ZAR (108 USD) per individual with a standard deviation
of 2247 ZAR (176 USD).

#### 136 Study setting

KwaZulu-Natal was the province in South Africa with the highest estimated HIV prevalence of 22% among adults aged 15 years and older in 2022 [1], totaling approximately 1.9 million adults [16]. An estimated 52% of the population in KwaZulu-Natal resided in rural areas [17], and rural districts of KwaZulu-Natal had the highest estimated HIV prevalence in South Africa of greater than 28% [18]. At the end of 2022, 31% of 15-64 year olds residing in KwaZulu-Natal were unemployed [19] and the average monthly earnings of employees in the formal nonagricultural sector was 26,032 ZAR across South Africa [20].

#### 144 **Cost estimation**

145 Our primary analysis compared the cost of quarterly home delivery of ART (the pilot Deliver Health Study intervention) with the Standard of Care (SOC), i.e., clinic-based care with 146 147 three-month refill scripts, in KwaZulu-Natal province. Due to limited capacity for costing during 148 the trial (which was conducted during the COVID-19 pandemic), costs were collected 149 retrospectively, and the home-delivery and SOC costs relied on different data sources representing 150 different regions of KwaZulu-Natal, described further below. All costs were estimated from the 151 payer perspective to inform the South African NDoH's financial planning and strategy. To 152 quantify resource use [21], we first outlined program activities in a detailed Narrative Summary

153	for the Deliver	Health	Study (S	1 File)	which	further	informed	our	assumptions	regarding
154	programmatic in	nplemen	tation (S2	File). C	)ur prim	ary outc	omes of in	teres	t were:	

- 155 1) <u>Average annual cost per client</u>: the average annual cost per person living with HIV in the
- 156 Deliver Health Study or in KwaZulu-Natal
- 157 2) <u>Average annual cost per client virally suppressed</u>: the average annual cost per person living
- 158 with HIV who was virally suppressed in the Deliver Health Study or in KwaZulu-Natal.
- 159 In our secondary objective, costs for each mode of service delivery were disaggregated by cost
- 160 categories (personnel, vehicles and fuel, drugs, etc.) to understand the main cost drivers (detailed
- 161 methods in S2 File).
- 162 Costs were reported in 2022 USD. For costs originally reported in ZAR, we used the
- 163 World Bank GDP implicit deflator for South Africa [22] and the average ZAR-to-USD exchange
- rate in 2022 [23]. We deflated costs reported in USD using the US annual average Consumer
- 165 Price Index [24]. Capital items and other costs with a useful life of more than one year were
- discounted 3%. Full details of these adjustments are provided in S2 File.

#### 167 Costing of home delivery of ART and monitoring

For home-delivered refills, we conducted activity-based micro-costing for home-delivered 168 169 ART and monitoring in the Deliver Health Study in rural uMgungundlovu District of KwaZulu-170 Natal. We excluded costs for research-specific procedures (e.g., data collection, research-related personnel costs). Personnel salaries were obtained from the Deliver Health Study and South Africa 171 172 Department of Public Service and Administration [25]. To estimate personnel time, vehicle costs, 173 and fuel, we used recorded travel logs for the home delivery trips. We assumed the home-delivery 174 intervention was delivered by a team of a nurse, a driver, and a community outreach worker. Full 175 cost assumptions including staff time and vehicle costs are detailed in S2 File.

#### 176 Costing of clinic-based ART refills and care

To estimate costs for clinic-based care, we used provincial government expenditure data 177 for the full province of KwaZulu-Natal and scaled it to ART-specific care. We obtained actual 178 179 HIV/AIDS spending (i.e., the rectified budget) for financial years 2019 and 2020 from the South African National Treasury [26]. We then estimated the proportion of the HIV program budget used 180 181 for ART using a 2020 government HIV/AIDS spending report [27] and applied this proportion to the total 12-month HIV program budget. Full details for these calculations are in the S2 File. Of 182 183 note, clinic expenditure data covered both rural as well as urban areas in KwaZulu-Natal (e.g., the 184 major cities of Durban and Newcastle), where ART costs may be lower than in rural regions [4].

#### 185 Scenarios

For the home-delivered ART intervention, we modelled two sets of scenarios over a 12month time horizon: programmatic and at-scale. Our baseline estimation assumed three-month (quarterly) refills; in a sensitivity analysis we also estimated the costs of home delivery for sixand 12-month ART refill scripts starting after the first quarter. Costs of home-delivered ART for all scenarios were compared to the SOC, i.e., clinic-based care with three-month ART refill scripts. Full details of the estimation for all scenarios are in S2 File.

**192 Programmatic cost estimation** 

The primary cost was the programmatic scenario for home-delivered ART, which we estimated to reflect the resource requirements if home-delivered ART were implemented by the South African NDoH. Accordingly, we substituted staff salaries paid under the Deliver Health Study with corresponding salaries reported by the South African government [25]. The programmatic scenario assumed that ART was delivered by a team of two (nurse and driver) who spent approximately 3.5 hours a day for 3 days a week making home deliveries to support 81

clients in the Deliver Health Study, and that the program was also supported by a community
outreach worker and other operational staff (S2 File). In a sensitivity analysis, we also estimated a
second programmatic "as-observed" scenario using staff salaries from within the Deliver Health
Study.

#### 203 At-scale cost estimation

204 Given the low client volume within the pilot Deliver Health Study, we estimated a scenario where home delivery of ART was scaled up to accommodate a larger client volume. Granted that 205 206 within the Deliver Health Study, the maximum number of deliveries made in a given day was 16 207 visits and the average time per visit was 26 minutes (including driving), we estimated that the same 208 team could reasonably make 12 home deliveries a day for five days per week, spending 209 approximately six hours of their working day making home deliveries to clients and about two 210 hours to load and unload the delivery vehicle at the central office. This estimation assumed a 40-211 hour work week and 214 workdays a year (excluding weekends, holidays, and other leave). In 212 addition, we assumed an ART initiation visit (which includes HIV counselling) would take three 213 times as long as an ART refill visit, which was qualitatively informed by time-and-motion 214 observations conducted during January-February 2023 for an ongoing follow-up trial to the 215 Deliver Health Study (S2 File).

216 **Results** 

#### 217 **Programmatic scenarios**

For the 81 clients receiving home-delivered ART in the Deliver Health Study, cost of home delivery was substantially higher than provincial estimates for annual per-client facility-based ART costs. Specifically, we estimated that in the context of the pilot study the average annual cost per client receiving home-delivered ART refills was \$794 per client and \$907 per client virally

222 suppressed in the first year of intervention and \$714 per client and \$815 per client virally 223 suppressed for subsequent years, after subtracting paid client fees (Tables 1 and 2). In comparison, 224 the SOC was estimated to cost an average of \$167 annually per client and \$254 per client virally 225 suppressed. "As-observed" costs for home-delivered ART in the Deliver Health Study were somewhat higher in the primary programmatic scenario due to differences in assumptions around 226 227 staff salaries (\$819 per client and \$935 per client virally suppressed for quarterly refills in the first 228 year of intervention). Multi-month scripting scenarios (with six- and 12-monthly refills) further 229 reduced the cost of home-delivered ART, as shown in Table 2.

Table 1. Average annual cost per client and average annual cost per virally suppressed client by refill method within the context of the Deliver Health Study, under the programmatic scenario with 3-month ART refill scripts.

		client	Average annual cost per client virally suppressed									
Cost category	Home deliveryaFirst yearbSubsequent yearsN=81N=81				Clinic <sup>c,d</sup> N=1,925,698		Home d First year <sup>b</sup> N=71		lelivery <sup>e</sup> Subsequent years N=71		<b>Clinic</b> <sup>c,d</sup> N=1,270,961	
	2022 ZAR	2022 USD	2022 ZAR	2022 USD	2022 ZAR	2022 USD	2022 ZAR	2022 USD	2022 ZAR	2022 USD	2022 ZAR	2022 USD
			•			Cost (% o	f total cost)	•				
ART drugs	1,150 (9)	70 (9)	1150 (10)	70 (10)	1150 (42)	70 (42)	1,312 (9)	80 (9)	1,312 (10)	80 (10)	1,743 (42)	106 (42)
Buildings and administrative overhead	2,189 (17)	134 (17)	2,091 (18)	128 (18)	58 (2)	4 (2)	2,497 (17)	152 (17)	2,386 (18)	146 (18)	88 (2)	5 (2)
Communication	1,269 (10)	78 (10)	1,269 (11)	78 (11)	6 (0.22)	0.36 (0.22)	1,448 (10)	88 (10)	1,448 (11)	88 (11)	9 (0.22)	0.55 (0.22)
Equipment	1,200 (9)	73 (9)	150 (1)	9(1)	2 (0.06)	0.11 (0.06)	1,369 (9)	84 (9)	172 (1)	10(1)	3 (0.06)	0.16 (0.06)
Hiring and training	657 (5)	40 (5)	657 (6)	40 (6)	2 (0.09)	0.15 (0.09)	749 (5)	46 (5)	749 (6)	46 (6)	4 (0.09)	0.22 (0.09)
Materials and supplies	753 (6)	46 (6)	590 (5)	36 (5)	561 (20)	34 (20)	859 (6)	52 (6)	674 (5)	41 (5)	850 (20)	52 (20)
Personnel wages and benefits	4,354 (33)	266 (33)	4,354 (37)	266 (37)	960 (35)	59 (35)	4,968 (33)	303 (33)	4,968 (37)	303 (37)	1454 (35)	89 (35)
Vehicles and fuel	1,491 (11)	91 (11)	1,489 (13)	91 (13)	0.26 (0.01)	0.02 (0.01)	1,701 (11)	104 (11)	1,699 (13)	104 (13)	0.40 (0.01)	0.02 (0.01)
Total <sup>f</sup>	13,006	794	11,694	714	2,740	167	14,846	907	13,349	815	4,151	254

Abbreviations: ART = antiretroviral therapy, ZAR = South African Rand, USD = United States Dollars, HIV = Human Immunodeficiency Virus, UNAIDS = Joint United Nations

**233** Programme on HIV/AIDS.

<sup>a</sup>There were 81 people living with HIV on ART in the home-delivered ART refills group of the Deliver Health Study.

<sup>b</sup>Includes startup costs.

<sup>c</sup>The standard-of-care in South Africa is 3-month ART refills at clinics.

d'The total number of adults (aged 15 years and older) living with HIV in KwaZulu-Natal in September 2022 was 1,925,698 people. Source: <u>UNAIDS HIV sub-national estimates</u>
 <u>viewer</u>.

<sup>e</sup>There were 71 people living with HIV on ART who were virally suppressed at study exit in the home-delivered ART refills group of the Deliver Health Study.

<sup>t</sup>The average fee for home delivery service, about 4 USD, paid by clients in the home delivery intervention of the Deliver Health Study was subtracted from the programmatic costs

of implementing home delivery.

Table 2. Estimated cost implications of multi-month home-delivered and standard clinic-based ART refills and monitoring as-observed by

the South African National Department of Health with South African government salaries, under the programmatic scenario with 3-, 6-, and

#### 244 <u>12-month ART refill scripts.</u>

		Avera	ge annual (	cost per	client	Average annual cost per client virally suppressed						
					Home							
Scenario	First year <sup>a</sup> N=81		Subsequent years N=81		<b>Clinic</b> <sup>b</sup> N=1,925,698		First year <sup>a</sup> N=71		Subsequent years N=71		<b>Clinic</b> <sup>b</sup> N=1,270,961	
	2022 ZAR	2022 USD	2022 ZAR	2022 USD	2022 ZAR	2022 USD	2022 ZAR	2022 USD	2022 ZAR	2022 USD	2022 ZAR	2022 USD
Programmatic costs with 3-month refills	13,006	794	11,694	714	2,740	167	14,846	907	13,349	815	4,151	254
Programmatic costs with 6-month refills	10,014	612	9,337	570			11,424	698	10,652	651		
Programmatic costs with 12-month refills	8,261	504	7,521	459			9,424	576	8,581	524		

Abbreviations: ART = antiretroviral therapy, ZAR = South African Rand, USD = United States Dollars, HIV = Human Immunodeficiency Virus, UNAIDS = Joint United Nations

Programme on HIV/AIDS.

a Includes startup costs.

<sup>b</sup>The standard-of-care in South Africa is 3-month ART refills at clinics.

249

250

251	For home-delivered ART, the largest cost categories were personnel costs (33%), buildings
252	and overhead (17%), and vehicles and fuel (11%) for the first year of implementation (Fig 1A).
253	These proportions remained relatively stable for subsequent years (Fig 1B). For the SOC, the
254	largest costs were ART drugs (42%), personnel costs (35%), and materials and supplies (20%) for
255	each year of implementation (Fig 1A). Total annual costs by cost category are reported in the S3
256	File.
257	
258	Figure 1. Average annual cost per client (2022 USD) for home-delivered 3-month ART
259	refills vs. clinic-based 3-month ART refills (standard-of-care) by cost category in the
260	programmatic NDoH-implemented scenario. The NDoH scenario assumes fixed costs as
261	implemented in the Deliver Health Study and public sector clinical staff salaries instead of study
262	salaries.
263	(A) Home-delivered 3-month ART refills (first year costs) vs. standard-of-care. (B) Home-
264	delivered 3-month ART refills (subsequent year costs) vs. standard-of-care.
265	
266	At-scale scenarios
267	We estimated that if the home delivery team was working full-time (using the parameters
268	described in the methods), the team could feasibly make 12 home delivery stops per working day
269	and accommodate a client volume of 367 newly diagnosed people with HIV in the first year and
270	up to 642 clients in subsequent years. We estimated that this at-scale programmatic cost of home
271	delivery would be \$267 annually per client for home-delivered ART refills and monitoring in the
272	first year and \$183 in subsequent years (Table 3), in comparison to \$167 for clinic-based refills.

273 The average annual cost per client virally suppressed receiving home-delivered ART refills would

- be \$303 in the first year and \$208 in subsequent years (Table 3) vs. \$254 for clients receiving
- 275 clinic-based care.

Table 3. Estimated cost implications of multi-month home-delivered and standard clinic-based ART refills and monitoring provided at-scale 276 by the South African National Department of Health with South African government salaries, with 3-, 6-, and 12-month ART refill scripts.

277

by the south African National Department of Health with South African government salaries, with 5-, 0-, and 12-month AK1 renn scripts.													
	Average annual cost per client							Average annual cost per client virally suppressed					
		Home d	<b>Clinic</b> N=1,925,698		Home delivery								
Scenario	First year <sup>b</sup> N=367				Subsequent years N=642		First year <sup>b</sup> N=323		Subsequent years N=565		Clinic N=1,270,961		
	2022 ZAR	2022 USD	2022 ZAR	2022 USD	2022 ZAR	2022 USD	2022 ZAR	2022 USD	2022 ZAR	2022 USD	2022 ZAR	2022 USD	
At-scale programmatic costs with 3-month refills <sup>a</sup>	4,367	267	2,996	183	2,740	167	4,963	303	3,405	208	4,151	254	
At-scale programmatic costs with 6-month refills	3,681	225	2,900	177			4,183	255	3,296	201			
At-scale programmatic costs with 12-month refills	3,921	239	2,214	135			4,455	272	2,516	154			

278 Abbreviations: ART = antiretroviral therapy, ZAR = South African Rand, USD = United States Dollars, HIV = Human Immunodeficiency Virus, UNAIDS = Joint United Nations 279 Programme on HIV/AIDS.

280 <sup>a</sup>The standard-of-care in South Africa is 3-month ART refills.

281 <sup>b</sup>Includes startup costs.

Multi-month scripting further reduced the cost of home-delivered ART so that it was comparable or even lower in cost than SOC. With six-month ART refill scripts, the annual cost per client would be \$225 for home-delivered refills in the first year and \$177 for subsequent years, (compared to \$167 for the SOC), and the average cost per client virally suppressed would be \$255 in the first year and \$201 in subsequent years (vs. \$254 for the SOC). At-scale 12-month ART refills would be cost-saving after the first year: the annual cost per client would be \$135 in subsequent years (compared to \$167 for the SOC) (Table 3).

For three-month at-scale home delivered ART, the largest first-year costs were ART drugs (26%), personnel costs (22%), materials and supplies (17%), and buildings and overheads (12%) (Fig 2A). The rankings of cost categories remained the same for subsequent years (Fig 2B). Average client costs per cost category for the six-month refill programmatic and at-scale scenarios are reported in the S3 File, along with additional cost driver figures.

294

Figure 2. At-scale average annual cost per client (2022 USD) for home-delivered 3-month ART refills vs. clinic-based 3-month ART refills (standard-of-care) by cost category in the programmatic NDoH-implemented scenario. The NDoH scenario assumes fixed costs as implemented in the Deliver Health Study and public sector clinical staff salaries instead of study salaries.

300 (A) Home-delivered ART intervention (first year costs) vs. clinic-based ART refills. (B) Home301 delivered ART intervention (subsequent year costs) vs. clinic-based ART refills.

302

## 303 **Discussion**

304 In this costing study of home-delivered ART refills in a high-prevalence rural setting in 305 South Africa, we estimate that when delivered at scale, home delivery costs in a rural setting are 306 comparable to the SOC of clinic-based refills administered across both rural and urban settings. 307 Specifically, assuming a reasonable client volume of 12 home deliveries per day, we estimate that 308 the annual per-client cost of home-delivered ART is \$267 in the first year and \$183 in subsequent 309 years, as compared to the province-level average of \$167 for clinic-based refills; this corresponds 310 to a per-client incremental cost of \$100 in the first year and \$16 in subsequent years (Table 3). 311 These incremental costs were predominantly driven by differences in personnel requirements (Fig 312 1). Importantly, this comparison covers a rural setting for home-delivered ART and a combined 313 rural/urban setting for the SOC – the difference in setting may contribute to an increase in observed 314 incremental costs given prior literature from South Africa which suggests that the cost of 315 delivering ART is on average 7% more costly in rural areas than in urban areas [4]. Multi-month 316 scripting (six- and 12-months) even further reduced costs of home delivery compared with 317 standard clinic-based refills, and were either comparable (six-months) or cost-saving (12-months) 318 when provided at-scale after the first year (Table 3). The published Deliver Health Study results 319 demonstrated clinical effectiveness of home-delivered ART [14], and the present costing study 320 suggests that home-delivered ART can be feasibly scaled up in a high prevalence rural setting in 321 South Africa at modest incremental cost.

Our estimates somewhat differ from other costing studies for DSD and ART delivery in South Africa. Importantly, our estimates for the SOC using KwaZulu-Natal's provincial budget data (\$167 per client annually) are substantially lower than the estimates from the South African HIV investment case, which estimated that the average cost (in 2022 USD) for providing ART per client annually across South Africa was \$290 [28]. Using a lower comparator means that our

17

327 estimates of the incremental cost of home-delivered care are higher than would be if we compared 328 to the South African HIV investment case. Our estimated at-scale annual per-client costs of ART 329 with quarterly refills were higher than those observed in the DO ART Study, a study of 330 community-based ART conducted in the same region of rural South Africa (\$183 in this study, 331 compared with \$287 in the DO ART Study for subsequent years after adjusting for inflation as 332 shown in S2 File) [29]. While it is expected that home delivery costs might be higher than 333 community-based delivery of ART due to increased personnel and fuel costs, an approach like 334 home delivery would remove the physical access barrier for the client, which could result in better 335 retention in care and ART adherence. Finally, in line with other studies on multi-month scripting 336 from Southern Africa which have also found comparable clinical outcomes [30–33], we found that 337 that increasing the duration of ART scripts to six- and 12-months further reduced costs due to the 338 fewer follow-up visits.

339 Interestingly, the largest cost category for home-delivered ART was personnel wages and 340 benefits (33% in the baseline scenario) and not vehicle and fuel costs (11%). Personnel was the 341 largest cost for a number of reasons. First, within the Deliver Health Study, staff coordinated and 342 made individual home deliveries based on client delivery preferences. In addition, the protocol 343 required that clients were physically present at the time of delivery (vs. dropping off refills at their 344 front door). Thus, planning of delivery trips and routes driven were not always optimized. With a 345 greater volume of clients, optimized delivery algorithms adapted from routing science-guided 346 delivery in the private sector [34–36] could be useful in managing client delivery preferences and 347 delivery personnel time, and may ultimately lower programmatic costs. This point is evidenced by 348 our findings in the at-scale scenarios, in which ART drugs contributed the largest costs to the 349 home-delivery intervention in both three- and six-month refill scenarios. Second, we assumed that

programmatic implementation of home-delivered ART included a full-time professional nurse at grade 2 and a driver. These programmatic nurse salaries were in fact higher than the nurse staff salaries from the Deliver Health Study, which is generally not consistent with the literature [29,37]. Alternative team configurations with task shifting to lower cadre health workers (e.g., lower grade nurses or community health workers) could be tested in future work to determine effectiveness and efficiency. Finally, vehicles did not contribute a substantial portion of total estimated costs due to low diesel and vehicle costs relative to personnel costs.

357 In the Deliver Health Study, clients paid a one-time fee, tiered based on individuals' 358 income (US \$2, \$4, or \$6), for a six-month ART home delivery service (which was extended due 359 to COVID-19). User fees in general were well-accepted: in the Deliver Health Study, 98% of clients paid the full user fee for the home-delivery ART service and 100% reported willingness to 360 361 continue to pay a fee for the service due to its perceived convenience and flexibility [9]. Notably, 362 these client fees for the home delivery service did not substantially offset delivery costs (personnel, 363 vehicle, and fuel) in either the as-observed or at-scale scenarios. Moreover, the fee in the Deliver 364 Health Study covered home ART delivery service for six months, thus an annual service fee per 365 client would likely be higher (e.g., double that of the six-month service) in implementation. 366 However, the user fees still contributed to a modest reduction in programmatic costs and may 367 additionally have contributed to program effectiveness [38,39].

Our study had a number of limitations. First, as discussed above, our costing of homedelivered ART covered a rural setting while the SOC covered a rural and urban setting, likely leading to an overestimate of incremental costs [40]. In a related point, we did not obtain all costing inputs from a single source; however, we relied on either peer-reviewed studies or published data from the South African government. Third, our study included a low client volume from pilot

373 randomized controlled trial leading to higher costs per person. To account for the small sample 374 size, we modelled at-scale scenarios to accommodate a higher client volume; these findings were 375 more in line with estimates from the literature. Fourth, we estimated costs for TDF/FTC/EFV (the 376 regimen prescribed for Deliver Health Study participants); however, as of 2023, South Africa 377 recommends ART regimens containing DTG for greater adherence and viral suppression [15,41] 378 [42,43] – future costing studies should note this change in clinical guidelines. Fifth, while our 379 study was conducted from the payer perspective to reflect the stakeholder of interest, a societal 380 perspective could better capture benefits to clients (e.g., transportation costs, lost wages due to 381 time spent on clinic visits, childcare [9]). Sixth, this study uses the SOC as the comparison, but 382 does not compare to costs of other DSD models for HIV, such as the use of community package 383 lockers (smart lockers) being tested in an ongoing trial throughout rural KwaZulu-Natal [44]. 384 Finally, while the present study does not incorporate health outcomes, the estimates generated in 385 this study can be leveraged for future cost-effectiveness analysis.

National scale-up of DSD models for HIV treatment, tailored to specific patient 386 387 populations and geographies, are needed in South Africa. A number of alternative ART dispensing 388 mechanisms have demonstrated improved medication adherence and retention compared to clinic 389 care, including home delivery service, community package lockers, and automated pharmacy 390 dispensing units [45]. These methods, particularly when clients can flexibly choose the most 391 convenient option, can strengthen individuals' commitment to care [46,47]. Additionally, 392 community-based ART resupply can increase coverage in rural areas [48] and reduce clinic 393 congestion [49]. At scale, home-delivered ART could be optimized using a centralized warehouse 394 to fulfill and dispatch delivery trucks that synchronize deliveries to neighboring locations, similar 395 to what is used in the private sector by Amazon [50]. These warehouses could even be used for

396 other chronic medications as part of the Centralised Chronic Medicine Dispensing and Distribution 397 [51], freeing up clinics and pharmacies to focus on clients with health care needs other than refills. 398 Drone delivery, which has successfully been tested in other African countries including Uganda 399 (for ART) and Malawi (for transportation of lab samples), offers a promising cost-effective 400 solution for rural areas [52,53]. In fact, Amazon has recently begun implementing home delivery 401 of medications via drones in the US [54]. These innovative methods hold promise for addressing 402 the hard-to-reach and high prevalence populations in rural South Africa, where interventions 403 increasing early adoption of and adherence to ART can be highly cost-effective (increases cost-404 effectiveness relative to the base-case by 23% in a rural areas of South Africa, compared to 1.1% 405 in urban areas) [4]. Future research should explore the costs and outcomes of various innovative 406 approaches compared to traditional clinic-based care.

### 407 **Conclusion**

408 Our costing study is a novel evaluation to quantify the costs associated with 409 implementing home-delivered ART and monitoring in rural South Africa. Implementing home-410 delivered ART and monitoring costs more on average annually per client and per client virally 411 suppressed compared to standard three-month clinic-based ART refills in KwaZulu-Natal, but 412 incremental costs were reduced when home delivery was scaled to a larger client volume and 413 potentially even cost-saving when using six- and 12-month refill scripts. The findings of this 414 study could help inform the South African NDoH's strategy to meet the 95-95-95 targets by 415 focusing on the scale-up of novel DSD methods, such as home-delivered ART, to promote long-416 term retention in HIV care while reducing patient load at public health clinics.

# 417 Acknowledgements

- 418 We would like to thank the Deliver Health Study Team and the individuals who
- 419 participated in the study.

## 420 **References**

421	1.	Human Sciences Research Council. SABSSM VI The Sixth South African National HIV
422		Prevalence, Incidence, Behaviour and Communication Survey: Summary Sheet. Cape
423		Town; 2023.
424	2.	Simbayi L, Zuma K, Zungu N, Moyo S, Marinda E, Jooste S, et al. South African
425		National HIV Prevalence, Incidence, Behaviour and Communication Survey, 2017. Cape
426		Town; 2019. Available: https://hsrc.ac.za/uploads/pageContent/10779/SABSSM V.pdf
427	3.	Malakoane B, Heunis JC, Chikobvu P, Kigozi NG, Kruger WH. Public health system
428		challenges in the Free State, South Africa: a situation appraisal to inform health system
429		strengthening. BMC Health Serv Res. 2020;20: 58. doi:10.1186/s12913-019-4862-y
430	4.	Mbonigaba J, Oumar SB. The cost-effectiveness of major HIV/AIDS interventions in
431		rural and urban areas in South Africa. Int J Econ Bus Res. 2017;13: 413.
432		doi:10.1504/IJEBR.2017.084387
433	5.	Grimsrud A, Wilkinson L. Acceleration of differentiated service delivery for HIV
434		treatment in sub-Saharan Africa during COVID-19. J Int AIDS Soc. 2021;24.
435		doi:10.1002/jia2.25704
436	6.	World Health Organization. Consolidated guidelines on HIV prevention, testing,
437		treatment, service delivery and monitoring: recommendations for a public health
438		approach. Geneva; 2021. Available:
439		https://www.who.int/publications/i/item/9789240031593
440	7.	Nicol E, Jama NA, Mehlomakulu V, Hlongwa M, Pass D, Basera W, et al. Enhancing
441		linkage to HIV care in the "Universal Test and Treat" era: Barriers and enablers to HIV
442		care among adults in a high HIV burdened district in KwaZulu-Natal, South Africa. BMC

443 Public Health. 2023;23: 1756. doi:10.1186/s12889-023-16576-w

- 8. Iwuji C, Chimukuche RS, Zuma T, Plazy M, Larmarange J, Orne-Gliemann J, et al. Test
- but not treat: Community members' experiences with barriers and facilitators to universal
- antiretroviral therapy uptake in rural KwaZulu-Natal, South Africa. Yotebieng M, editor.

447 PLoS One. 2020;15: e0239513. doi:10.1371/journal.pone.0239513

- 448 9. Ntinga X, Musiello F, Pita T, Mabaso N, Celum C, Szpiro A, et al. People living with
- 449 HIV's perspectives of acceptability of fee for home delivery of ART: a qualitative study.

450 BMC Health Serv Res. 2024;24: 88. doi:10.1186/s12913-023-10533-4

- 451 10. Brey Z, Mash R, Goliath C, Roman D. Home delivery of medication during Coronavirus
- disease 2019, Cape Town, South Africa: Short report. African J Prim Heal care Fam Med.
  2020;12: e1-e4. doi:10.4102/phcfm.v12i1.2449
- 454 11. Mash RJ, Schouw D, Daviaud E, Besada D, Roman D. Evaluating the implementation of

455 home delivery of medication by community health workers during the COVID-19

456 pandemic in Cape Town, South Africa: a convergent mixed methods study. BMC Health

457 Serv Res. 2022;22: 98. doi:10.1186/s12913-022-07464-x

458 12. Huber A, Pascoe S, Nichols B, Long L, Kuchukhidze S, Phiri B, et al. Differentiated

459 Service Delivery Models for HIV Treatment in Malawi, South Africa, and Zambia: A

460 Landscape Analysis. Glob Heal Sci Pract. 2021;9: 296–307. doi:10.9745/GHSP-D-20-

- 461 00532
- 462 13. Barnabas R V, Szpiro A, Ntinga X, Mugambi ML, Krows ML, Schaafsma TT, et al. Fee
- 463 for home delivery and monitoring of ART raises viral suppression in South Africa.
- 464 Conference on Retroviruses and Opportunistic Infections (CROI). 2021. Available:
- 465 https://www.croiconference.org/abstract/fee-for-home-delivery-and-monitoring-of-art-

- 466 raises-viral-suppression-in-south-africa/
- 467 14. Barnabas R V, Szpiro AA, Ntinga X, Mugambi ML, van Rooyen H, Bruce A, et al. Fee
- 468 for home delivery and monitoring of antiretroviral therapy for HIV infection compared
- 469 with standard clinic-based services in South Africa: a randomised controlled trial. Lancet
- 470 HIV. 2022;9: e848–e856. doi:10.1016/S2352-3018(22)00254-5
- 471 15. Republic of South Africa National Department of Health. 2023 ART Clinical Guidelines
- 472 for the Management of HIV in Adults, Pregnancy and Breastfeeding, Adolescents,
- 473 Children, Infants and Neonates. Pretoria; 2023. Available:
- 474 https://www.differentiatedservicedelivery.org/wp-content/uploads/National-ART-Clinical-
- 475 Guideline-2023\_06\_06-version-3-Web.pdf
- 476 16. UNAIDS. HIV sub-national estimates viewer. In: UNAIDS [Internet]. 2024 [cited 15 Feb
- 477 2024]. Available: https://naomi-spectrum.unaids.org/
- 478 17. South African Department of Water and Sanitation. WSA: PROVINCIAL [NAT]
- 479 DEMOGRAPHY. 2024 [cited 9 Apr 2024]. Available:
- 480 https://ws.dws.gov.za/wsks/DefaultList.aspx?SubjectAreaID=1&DataTopicDetailID=92&
- 481 DisplayTypeId=1&PerspectiveID=0&LvIID=10&DataTopicID=1
- 482 18. South Africa Estimates and Modelling Technical Working Group. South Africa District
- 483 HIV Estimates. 2023 [cited 9 Mar 2024]. Available: https://www.hivdata.org.za/
- 484 19. Statistics South Africa. Statistical Release P0211 Quarterly Labour Force Survey Quarter
- 485 4: 2022. Pretoria; 2023. Available:
- 486 https://www.statssa.gov.za/publications/P0211/P02114thQuarter2022.pdf
- 487 20. Statistics South Africa. Statistical Release P0277 Quarterly employment statistics (QES)
- 488 December 2022. Pretoria; 2023. Available:

489		https://www.statssa.gov.za/publications/P0277/P0277December2022.pdf
490	21.	Vassall A, Sweeney S, Kahn J, Gomez GB, Bollinger L, Marseille E, et al. Reference

- 491 Case for Estimating the Costs of Global Health Services and Interventions. 2017.
- 492 Available:
- 493 https://researchonline.lshtm.ac.uk/id/eprint/4653001/1/vassall\_etal\_2018\_reference\_case\_
- 494 for\_estimating\_costs\_global\_health\_services.pdf
- 495 22. The World Bank. GDP deflator (base year varies by country) South Africa. In: The

496 World Bank [Internet]. 2024 [cited 10 Dec 2023]. Available:

- 497 https://data.worldbank.org/indicator/NY.GDP.DEFL.ZS?locations=ZA
- 498 23. Exchange Rates UK. US Dollar (USD) to South African Rand (ZAR) exchange rate
- 499 history. In: Exchange Rates UK [Internet]. 2024 [cited 10 Dec 2023]. Available:
- 500 https://www.exchangerates.org.uk/USD-ZAR-exchange-rate-history.html
- 501 24. U.S. Bureau of Labor Statistics. Databases, Tables & Calculators by Subject: Consumer
- 502 Price Index for All Urban Consumers (CPI-U). In: U.S. Bureau of Labor Statistics
- 503 [Internet]. 2024 [cited 19 Mar 2024]. Available:
- 504 https://data.bls.gov/timeseries/CUUR0000SA0
- 505 25. South Africa Department of Public Service and Administration. Appendices A to H4 to
- 506 COLA 2021: 2019 and 2021 salary scales, with translation keys, for employees on salary
- 507 levels 1 to 12 and those employees covered by Occupation Specific Dispensations
- 508 (OSDs). In: South Africa Department of Public Service and Administration [Internet].
- 509 2021 [cited 8 Feb 2024]. Available:
- 510 https://www.dpsa.gov.za/dpsa2g/documents/rp/2021/Appendices A to H4 to COLA
- 511 2021.xlsx

- 512 26. South African National Treasury. Budgeted and Actual Provincial Expenditure. In:
- 513 Vulekamali [Internet]. 2024 [cited 29 Jan 2024]. Available:
- 514 https://vulekamali.gov.za/datasets/budgeted-and-actual-provincial-expenditure/budgeted-
- 515 and-actual-provincial-expenditure
- 516 27. Davén J, Khoele A, Manamela L. 2020 HIV/AIDS Component of the HIV, TB, Malaria
- and Community Outreach Grant an analysis of expenditure per output and options for
- 518 future reform. Pretoria; 2021. Available: https://www.gtac.gov.za/pepa/wp-
- 519 content/uploads/2021/11/HIV-TB-Spending-Review-Report.pdf
- 520 28. Meyer-Rath G, van Rensburg C, Chiu C, Leuner R, Jamieson L, Cohen S. The per-patient
- 521 costs of HIV services in South Africa: Systematic review and application in the South
- 522 African HIV Investment Case. McCreesh N, editor. PLoS One. 2019;14: e0210497.
- 523 doi:10.1371/journal.pone.0210497
- 524 29. Barnabas R V, Szpiro AA, van Rooyen H, Asiimwe S, Pillay D, Ware NC, et al.
- 525 Community-based antiretroviral therapy versus standard clinic-based services for HIV in
- 526 South Africa and Uganda (DO ART): a randomised trial. Lancet Glob Heal. 2020;8:
- 527 e1305–e1315. doi:10.1016/S2214-109X(20)30313-2
- 528 30. Benade M, Nichols BE, Fatti G, Kuchukhidze S, Takarinda K, Mabhena-Ngorima N, et al.
- 529 Economic evaluation of a cluster randomized, non-inferiority trial of differentiated service
- 530 delivery models of HIV treatment in Zimbabwe. Pai M, editor. PLOS Glob Public Heal.
- 531 2023;3: e0000493. doi:10.1371/journal.pgph.0000493
- 532 31. Nichols BE, Cele R, Lekodeba N, Tukei B, Ngorima-Mabhena N, Tiam A, et al.
- 533 Economic evaluation of differentiated service delivery models for HIV treatment in
- Lesotho: costs to providers and patients. J Int AIDS Soc. 2021;24. doi:10.1002/jia2.25692

535	32.	Le Tourneau N,	Germann A,	Thompson	RR, Ford N	, Schwartz S,	Beres L, et al.

- 536 Evaluation of HIV treatment outcomes with reduced frequency of clinical encounters and
- antiretroviral treatment refills: A systematic review and meta-analysis. Newell M-L,
- editor. PLOS Med. 2022;19: e1003959. doi:10.1371/journal.pmed.1003959
- 539 33. Lewis L, Sookrajh Y, van der Molen J, Khubone T, Sosibo P, Maraj M, et al. Clinical
- 540 outcomes after extended 12-month antiretroviral therapy prescriptions in a
- 541 community-based differentiated HIV service delivery programme in South Africa: a
- retrospective cohort study. J Int AIDS Soc. 2023;26. doi:10.1002/jia2.26164
- 543 34. Zhang J, Lam WHK, Chen BY. On-time delivery probabilistic models for the vehicle
- routing problem with stochastic demands and time windows. Eur J Oper Res. 2016;249:
- 545 144–154. doi:10.1016/j.ejor.2015.08.050
- 546 35. Wang J, Zhou Y, Wang Y, Zhang J, Chen CLP, Zheng Z. Multiobjective Vehicle Routing
- 547 Problems With Simultaneous Delivery and Pickup and Time Windows: Formulation,
- 548 Instances, and Algorithms. IEEE Trans Cybern. 2016;46: 582–594.
- 549 doi:10.1109/TCYB.2015.2409837
- 550 36. Chen X, Zhang Z, Fries R. Development and implementation of algorithms for vehicle

routing during a no-notice evacuation. Loxton R, editor. Cogent Math. 2016;3: 1163767.

- doi:10.1080/23311835.2016.1163767
- 553 37. Roberts DA, Barnabas R V, Abuna F, Lagat H, Kinuthia J, Pintye J, et al. The role of
- costing in the introduction and scale-up of HIV pre-exposure prophylaxis: evidence from
- 555 integrating PrEP into routine maternal and child health and family planning clinics in
- 556 western Kenya. J Int AIDS Soc. 2019;22. doi:10.1002/jia2.25296
- 557 38. Ashraf N, Berry J, Shapiro JM. Can Higher Prices Stimulate Product Use? Evidence from


- a Field Experiment in Zambia. Am Econ Rev. 2010;100: 2383–2413. Available:
- http://www.aeaweb.org/articles.php?doi=10.1257/aer.100.5.2383
- 560 39. El-Shal A, Cubi-Molla P, Jofre-Bonet M. Are user fees in health care always evil?
- 561 Evidence from family planning, maternal, and child health services. Econ Anal Policy.
- 562 2021;72: 506–529. doi:10.1016/j.eap.2021.08.009
- 563 40. Statistics South Africa. Statistics South Africa Provincial Profile 2004: KwaZulu-Natal.
- 564 Pretoria; 2006. Available: https://www.statssa.gov.za/publications/Report-00-91-
- 565 05/Report-00-91-052004.pdf
- 566 41. World Health Organization. WHO recommends dolutegravir as preferred HIV treatment
- option in all populations. In: World Health Organization [Internet]. 2019 [cited 7 Mar
- 568 2024]. Available: https://www.who.int/news/item/22-07-2019-who-recommends-
- 569 dolutegravir-as-preferred-hiv-treatment-option-in-all-populations
- 570 42. The NAMSAL ANRS 12313 Study Group. Dolutegravir-Based or Low-Dose Efavirenz-
- 571 Based Regimen for the Treatment of HIV-1. N Engl J Med. 2019;381: 816–826.
- 572 doi:10.1056/NEJMoa1904340
- 573 43. Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, et al.
- 574 Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. N Engl J Med.
- 575 2019;381: 803–815. doi:10.1056/NEJMoa1902824
- 576 44. van Heerden A, Szpiro A, Ntinga X, Celum C, van Rooyen H, Essack Z, et al. A
- 577 Sequential Multiple Assignment Randomized Trial of scalable interventions for ART
- 578 delivery in South Africa: the SMART ART study. Trials. 2023;24: 32.
- 579 doi:10.1186/s13063-022-07025-x
- 580 45. Mash R, Christian C, Chigwanda R V. Alternative mechanisms for delivery of medication

- in South Africa: A scoping review. South African Fam Pract. 2021;63: e1–e8.
- 582 doi:10.4102/safp.v63i1.5274
- 583 46. Wieber F, Thürmer JL, Gollwitzer PM. Promoting the translation of intentions into action
- 584 by implementation intentions: behavioral effects and physiological correlates. Front Hum
- 585 Neurosci. 2015;9. doi:10.3389/fnhum.2015.00395
- 586 47. Hagger MS, Luszczynska A, de Wit J, Benyamini Y, Burkert S, Chamberland P-E, et al.
- 587 Implementation intention and planning interventions in Health Psychology:
- 588 Recommendations from the Synergy Expert Group for research and practice. Psychol
- 589 Health. 2016;31: 814–839. doi:10.1080/08870446.2016.1146719
- 590 48. Luque-Fernandez MA, Van Cutsem G, Goemaere E, Hilderbrand K, Schomaker M,
- 591 Mantangana N, et al. Effectiveness of Patient Adherence Groups as a Model of Care for
- 592 Stable Patients on Antiretroviral Therapy in Khayelitsha, Cape Town, South Africa.
- 593 Dowdy DW, editor. PLoS One. 2013;8: e56088. doi:10.1371/journal.pone.0056088
- 594 49. van Heerden A, Ntinga X, Lippman SA, Leslie HH, Steward WT. Understanding the
- 595 factors that impact effective uptake and maintenance of HIV care programs in South
- African primary health care clinics. Arch Public Heal. 2022;80: 221. doi:10.1186/s13690-
- **597** 022-00975-3
- 598 50. Lenharo M. The science behind grouping package deliveries. In: Amazon Science
- [Internet]. 2022 [cited 14 Mar 2024]. Available: https://www.amazon.science/latestnews/the-science-behind-grouping-amazon-package-deliveries
- 601 51. South Africa National Department of Health. dablapmeds. In: South Africa National
- 602 Department of Health [Internet]. 2024 [cited 7 Mar 2024]. Available:
- 603 https://www.health.gov.za/ccmdd/


- 604 52. UNICEF Malawi. The Drones Factsheet. 2018. Available:
- 605 https://www.unicef.org/malawi/reports/drones-factsheet
- 606 53. Goad K. How drones are being used to deliver lifesaving HIV drugs to remote areas of the
- 607 world. Johnson & Johnson. 21 Jul 2021. Available:
- 608 https://www.jnj.com/innovation/medical-drones-deliver-hiv-medicine
- 609 54. Amazon Staff. Get medications faster with drone delivery from Amazon Pharmacy.
- 610 Amazon News. Oct 2023. Available: https://www.aboutamazon.com/news/retail/amazon-
- 611 pharmacy-amazon-air-prescription-drone-delivery
- 612
- 613

# 614 Supporting information captions


- 615 S1 File. Narrative summary of the Deliver Health Study.
- 616 S2 File. Additional methods.
- 617 S3 File. Additional results.




# Fig 1A



# Fig 1B



# Fig 2A



# Fig 2B